Clinical Trials
9 trialsNCT00942734 2025-05-01
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00448240 2025-03-18
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
Henry Ford Health System
Phase 2/3 Terminated
NCT00966472 2020-04-21
Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
Ottawa Hospital Research Institute
Phase 1 Completed
NCT00563784 2019-11-20
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00369512 2017-05-30
RAD0503
University of Alabama at Birmingham
Phase 2 Completed
NCT01009203 2015-08-10
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00476476 2015-05-07
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00673049 2013-07-24
NSCLC
Pfizer
Phase 3 Terminated
NCT00113347 2012-02-27
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1 Completed